Investors
Welcome on board!
Company overview

Pharnext is an advanced clinical-stage biopharmaceutical company committed to developing novel innovative therapeutics for orphan and common diseases with high unmet medical need.

Our proprietary R&D platform, PLEOTHERAPY™, systematically leverages genomic big data and AI to identify synergistic combinations of approved drugs or NCEs to generate new therapeutics with the potential to safely and effectively target and treat diseases.

˪ Disclosure of the total number of voting rights and shares composing the share capital

Date

Number of shares composing the share capital

Theoretical number of voting rights

30th June 2020

19,185,328*

23,470,547

* including 2,155,000 new shares issued from the equity line financing with Kepler Cheuvreux announced on Novembre 19th 2019.

˪ Stock information

Stock Market

Euronext Growth Paris

Mnemo

ALPHA

Bloomberg

ALPHA/FR – Reuters: ALPHA.PA

ISIN Code


FR0011191287

Closing date


31 December

First day of cotation


18 July 2016

Number of shares

19,185,328

Indices


EnterNext© PEA-PME 150,

Euronext Growth All-Share, Next Biotech, PEA

Liquidity contract


Gilbert Dupont

Eligible to PEA-PME (French fiscal advantage)

Share price


Analysts coverage

Kepler Cheuvreux : Damien Choplain - email
Gilbert Dupont : Guillaume Cuvillier - email
Edison Group : Nathaniel Calloway - email

General meeting

Contact

Have a question for Pharnext?

Want to join our team?

Contact
˪ For investors

Pharnext Headquarters

Pharnext

46 Rue Saint-Lazare

75009 Paris, France

+33 (0)1 41 09 22 30

inverstors@pharnext.com

United States

Stern Investor Relations

Janhavi Mohite
+1 212-362-1200

janhavi.mohite@sternir.com

International

Consilium Strategic Communications

Mary-Jane Elliott
Sukaina Virji
Alexandra Harrison

pharnext@consilium-comms.com

France

Actifin France

Stéphane Ruiz

+33 (0)1 56 88 11 15

sruiz@actifin.fr
Contact
˪ For media

Pharnext Headquarters

Pharnext

46 Rue Saint-Lazare

75009 Paris

+33 (0)1 41 09 22 30

contact@pharnext.com

International

Consilium Strategic Communications

Mary-Jane Elliott
Sukaina Virji
Alexandra Harrison

pharnext@consilium-comms.com

France

Ulysse Communication

Bruno Arabian

+33 (0)1 81 70 96 30

barabian@ulysse-
communication.com

United States

RooneyPartners

Jeffrey Freedman

+1 646 432 0191

jfreedman@rooneyco.com